ATROMEDIUM SIGNALFINANCIAL10-K

ATRO expanded operations to Germany while achieving substantially higher gross profit, though this was offset by a significant decline in stockholders' equity and increased debt burden.

The company appears to be in a growth phase with meaningful gross profit expansion, but the substantial decrease in equity paired with higher liabilities suggests either significant capital restructuring or dilutive financing activities. The geographic expansion to Germany indicates strategic investment in European operations, which could support longer-term growth but may be straining the balance sheet in the near term.

Comparing 2026-02-26 vs 2025-03-05View on EDGAR →
FINANCIAL ANALYSIS

ATRO's financial profile shows mixed signals with gross profit growing substantially while R&D expenses declined modestly, suggesting improved operational efficiency or favorable market conditions. However, the balance sheet deteriorated meaningfully with stockholders' equity falling 45% while total liabilities increased 44%, indicating significant capital structure changes or potential dilution. The near-doubling of cash reserves provides some cushion, but the overall leverage increase warrants monitoring given the company's changed financial risk profile.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+95.8%
$9.3M$18.2M

Cash position surged 95.8% — strong cash generation or capital raise providing significant financial cushion.

Gross Profit
P&L
+53.4%
$168.3M$258.2M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Stockholders Equity
Balance Sheet
-45.3%
$256.1M$140.1M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Liabilities
Balance Sheet
+44.3%
$392.7M$566.6M

Liabilities grew 44.3% — significant increase in debt or obligations, assess impact on financial flexibility.

Interest Expense
P&L
-42.3%
$1.8M$1.0M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

R&D Expense
P&L
-16.6%
$52.1M$43.5M

R&D spending cut 16.6% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-05
ADDED
), Canada, France and Germany, as well as engineering offices in Ukraine and India.
The Company has two reportable segments, Aerospace and Test Systems.
The Aerospace segment designs and manufactures products for the global aerospace and defense industry.
Our Test Systems segment designs, develops, manufactures and maintains automated test systems that support the aerospace and defense, communications and mass transit industries.
During 2025, this segment s sales were divided 75% to the commercial transport market, 15% to the military aircraft market, 9% to the general aviation market and 1% to other markets.
+7 more — sign up free →
REMOVED
), Canada and France, as well as engineering offices in Ukraine and India.
Refinancing On July 11, 2024, the Company completed a financing transaction that refinanced its previous credit facilities.
The refinancing consisted of an amendment and restatement of the Company s asset-based revolving credit facility with a principal amount available to be borrowed thereunder of $200.0 million (the ABL Revolving Credit Facility ), with amounts borrowed thereunder carrying an interest rate of SOFR plus between 2.50% to 3.00%.
The Company also entered into a $55.0 million term loan facility (the Term Loan Facility ) at an interest rate of SOFR plus a term SOFR plus between 5.50% to 6.75%.
On November 25, 2024, the Company amended the ABL Revolving Credit Facility increasing the revolving credit line to $220.0 million with an interest rate of SOFR plus 2.75% to 3.25% (an increase of 0.25% to each such applicable margin).
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →